Novel biomarkers for glioblastoma brain cancer have been identified in bodily fluids. The discovery may lead to a new, simple, non-invasive blood test to detect brain cancer in the future.
In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and glioblastoma multiforme tumors.
A new study reports a genetically modified poliovirus therapy has been shown to improve long term survival rates in recurrent glioblastoma brain cancer patients. Researchers say the therapy had a three year survival rate for 21 percent of participants in a phase 1 clinical trial, compared to just 4% of patients who received more standard treatments.
Researchers report the addition of an FDA approved chemotherapy drug called hydroxyyurea to temozolomide helps to increase survival rates in animal models of glioblastoma.
A new study discovers molecular pathways that could lead to new targeted therapies which may potentially treat Glioblastoma, the most common and lethal form of brain cancer in adults.
Researchers detail the use of a drug that may help block the way glioblastoma brain cancer cells respond to fluid flow. The finding could lead to stopping glioblastoma from spreading.
“We identified a subset of brain tumor cells that are slower growing or remain at rest, and appear to be the source of cancer recurrence after standard therapy in which the drug temozolomide is given to stop the tumor’s growth,” said Dr. Luis Parada. “Current therapy targets fast-growing tumor cells but not those responsible for new tumors. To the best of our knowledge, this is the first identification of a cancer stem-like cell in a spontaneously forming tumor inside a mammal.”
Cannabidiol (CBD) appears to slow the growth of glioblastoma brain cancer cells in both animal and human cell lines. CBD's anti-cancer actions target mitochondria, causing them to dysfunction and release harmful reactive oxygen species. Cancer cells treated with CBD exhibited significant decreases in mitochondrial activity.
A new nanocarrier meets the size and stability to effectively pass the BBB and deliver drugs to glioblastoma multiforme brain cancer.
A new drug has been cleared for human trials in patients with anaplastic astrocytoma and glioblastoma brain cancers. The drug, PAC-1, is reported to spur cancer cells to self destruct and has proven to be effective in animal models of brain cancers.